Here, expressions of VEGF and CD34 in the transplanted tumor tissues after bevacizumab treatment were lower, but HIF-1α expression was significantly higher than those in the control group, suggesting that the anti-angiogenic property of bevacizumab may exacerbate the hypoxic condition in the TME. The gene discussed is CD34; the disease is neoplasm.